Welcome to Flow Pharma Inc.

Page Loading...

Menu

Powerful Immunotherapy

in a Stable Dry Powder

Delivery Methods

  • Anti-Virus – inhalation & intramuscular

  • Anti-Cancer – intranodal & intramuscular

No animal-sourced material. No live or dead virus. Does not rely on DNA or RNA transcription.

Rapidly Scalable


FLOVID-20

A New Vaccine for COVID-19. Administered by inhaler. FLOVID-20 is designed to treat and prevent all known variants by inhaler or by injection.

 

X-rays of COVID-19 exposed monkeys.

 

The left monkey was treated with inhaled FLOVID-20.

 
Under Development, FDA approval required.


New Hope for Treatment-Resistant Breast Cancer

FlowVax is an immunotherapy solution which targets a marker on many types of cancer cells which is not present on normal cells.

 

FlowVax has been shown to slow triple negative breast cancer growth in a mouse model.

 
Under Development, FDA approval required.


About Us

We are Flow Pharma.

The Science

The research behind the solution.

Latest News

Stay up to date.

Investor Relations

Contact our team.
blob-1
blob-2
Our Mission

Flow Pharma is dedicated to immunotherapy innovation.

Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.

IMG_5984(1)

IMG_6307(1)

IMG_6308(1)

IMG_6423

IMG_7345

IMG_7369

IMG_7369

IMG_7369

Product Portfolio


FLOVID-20

COVID-19, FLOVID-20

An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

Learn More

FlowVax Ebola/Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target these viruses, long-lasting infection prevention is attainable.

Learn More

FlowVax BreastCA

Cancer

A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

Learn More

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

Learn More




Subscribe to Flow Pharma Updates